Science Lab

Where Cures Thrive.

We're on a mission to transform the biomanufacturing sector through the creation and delivery of a new Plug and Manufacture solution. GeneSuites will provide an ecosystem where cures thrive for patients, patient families, and future generations.

Accelerating Speed to Market with High-Performance Shell

GeneSuites offers a novel solution for biopharmaceutical companies to accelerate speed to market while minimizing risk. Our High-Performance Shell structure offers both the flexibility of a cold shell combined with the optionality of turnkey real estate.

 

The Opportunity

Accelerate
Speed to Market

Unprecedented approach to building flexible and equipped cGMP facilities that can easily adapt to new modalities and processes

Maximize
Quality Control

Through a hybrid approach, maintain total control of manufacturing process and environment

Secure
Intellectual Property

Eliminate the need for contracting with third-parties (CDMO/CMOs) and revealing methodologies

Experience
Higher Margins

Reduce cost per batch / dose through optimized operations

Maintain Flexibility

Ability to accommodate multiple therapies, processes and technologies within the same facility

Leverage Scalability

Can accommodate pre-clinical through commercial scale
(or capacity)

Abstract Futuristic Background

Developed with and validated by world-class life science experts and Chief Manufacturing Officers.

 

Expanding Across 
Major Life Science Clusters

GeneSuites has entered the Raleigh-Durham market with Catalyst BioCampus and will continue to expand across major life science markets in the United States and abroad.

GS_Map.png
220517_Catalyst_CampusEntry_LR.jpg
LOGO_Catalyst_01.png

First of its Kind:
High-Performance Shell in North Carolina

In partnership with affiliates of Apollo Global Management, GeneSuites is developing Catalyst BioCampus, a three-building cGMP biomanufacturing campus located in Raleigh-Durham, NC.

 

Already under construction, Catalyst BioCampus is designed to accelerate critical manufacturing capacity for cell & gene therapy, monoclonal antibody – as well as other modalities ­– by 9-15 months.